Sanofi (SNY) issued the following statement regarding rule 2.12 of the takeover rules: "Sanofi S.A. confirms that any offer for Horizon Therapeutics plc, if made by Sanofi, will be solely in cash. There is no certainty that any offer will be made, nor as to the terms on which any such offer may be made, if forthcoming."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SNY:
- Horizon Therapeutics price target raised to $125 from $101 at Jefferies
- Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
- Sanofi reports Phase II/III study results for acoziborole published in Lancet
- Horizon Therapeutics jumps 33% after deal talks with Amgen, Janssen, Sanofi
- Horizon Therapeutics confirms preliminary deal talks with Amgen, Janssen, Sanofi